Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.39 |
| ▸ | FABP7 | O15540 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | MDM4 | O15151 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7062622 | 1.00 | KMT2A (0.42) | KMT2AFABP5FABP7CASP3MDM2 | |
| SCHEMBL12314878 | 0.92 | KMT2A (0.41) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL30983406 | 0.92 | KMT2A (0.46) | KMT2AFABP5FABP7CASP3MDM2 | |
| SCHEMBL30278742 | 0.91 | KMT2A (0.47) | KMT2AFABP5FABP7CASP3MDM2 | |
| SCHEMBL22091999 | 0.91 | KMT2A (0.47) | KMT2AFABP5FABP7CASP3MDM2 | |
| SCHEMBL29521277 | 0.90 | KMT2A (0.41) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL16060098 | 0.90 | KMT2A (0.41) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL31000664 | 0.89 | KMT2A (0.36) | KMT2AFABP5FABP7EPHX2 | |
| SCHEMBL22092037 | 0.88 | KMT2A (0.39) | KMT2AFABP5FABP7MDM2EPHX2 | |
| SCHEMBL31688637 | 0.86 | KMT2A (0.36) | KMT2AFABP5FABP7CASP3MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4448097-A1 | PEPTIDE DUAL AGONISTS OF GIPR AND GLP2R | Bainan Biotech ApS (DK) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448098-A2 | PEPTIDES TRIPLE AGONISTS OF GIP, GLP-1 AND GLP-2 | Bainan Biotech ApS (DK) | 2024-10-23 | — | — | EP | disclosed |
| WO-2024133382-A1 | GLP1/GIP/NPY2 RECEPTOR TRIPLE AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-27 | — | — | WO | disclosed |
| CN-117940444-A | Caspase-2 inhibitor compounds | 金特速吉医疗有限责任公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4232459-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | Provincial Health Services Authority (CA) | 2023-08-30 | — | — | EP | disclosed |
| WO-2023111273-A1 | PEPTIDE DUAL AGONISTS OF GIPR AND GLP2R | BAINAN BIOTECH APS (DK) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023111278-A2 | PEPTIDES TRIPLE AGONISTS OF GIP, GLP-1 AND GLP-2 | BAINAN BIOTECH APS (DK) | 2023-06-22 | — | — | WO | disclosed |
| WO-2022082312-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-04-28 | — | — | WO | disclosed |